United States v. John Brooker

858 F.3d 983, 2017 WL 2466733, 2017 U.S. App. LEXIS 10152
Court of Appeals for the Fifth Circuit·Decided June 7, 2017·No. 16-10698·Published·Cited by 12 cases

Opinion

EDWARD C. PRADO, Circuit Judge:

Defendant-Appellant John Hoke Brook-er pleaded true to violating numerous conditions of his supervised release. The district judge accordingly revoked Brooker’s term of supervised release and sentenced him to an additional twenty-four months’ imprisonment. Brooker appeals this revocation. We AFFIRM.

I. BACKGROUND

In 2011, Brooker pleaded guilty to one count of possession of a counterfeit obligation under 18 U.S.C. § 472 and was thereafter sentenced to 70 months’ imprisonment and a three-year term of supervised release. Brooker’s term of supervised release began on June 26, 2015.

On May 10, 2016, the government moved to revoke Brooker’s term of supervised release. The government alleged Brooker had violated the conditions of his supervised release by: (1) using and possessing methamphetamine multiple times; (2) failing numerous drug tests; (3) refusing to participate in substance abuse treatment counseling; and (4) failing to make consistent payments toward a fíne imposed on him as part of his sentence. At a revocation hearing on May 12, 2016, Brooker pleaded true to these violations and the district court revoked Brooker’s term of supervised release. The district court then heard testimony, argument, and allocution from the defense. Thereafter, the district court detailed Brooker’s criminal history and sentenced him to 24 months’ imprisonment and no supervised release, noting that the previous supervision had not “done a bit of good.” Brooker objected to the length of the sentence and the court’s alleged failure to consider a drug treatment program in lieu of imprisonment. This appeal followed. On appeal, Brooker also argues the district court erred by failing to give him a meaningful opportunity for allocution because he was not permitted to address the court before the judge voiced his intent to revoke Brooker’s supervised release.

II. DISCUSSION

The decision to revoke supervised release is generally reviewed for an abuse of discretion. United States v. McCormick, 54 F.3d 214, 219 (5th Cir. 1995). We then “review a sentence imposed on revocation of supervised release under a ‘plainly unreasonable’ standard, in a two-step process.” United States v. Warren, 720 F.3d 321, 326 (5th Cir. 2013). First, we “ensure that the district court committed no significant procedural error.” Id. (quoting United States v. Kippers, 685 F.3d 491, 497 (5th Cir. 2012)). Second, “[i]f the district court’s sentencing decision lacks procedural error, this court ... considers the substantive reasonableness of the sentence imposed.” Id. (quoting Kippers, 685 F.3d at 497). “If we find the sentence unreasonable, we may reverse the district court only if we further determine ‘the error was obvious under existing law.’ ” Id. (quoting United States v. Miller, 634 F.3d 841, 843 (5th Cir. 2011)). Where a defendant fails to object before the district court, “errors resulting from a denial of the right of allocution under Rule 32 are subject to plain error review.” 1 United States v. Reyna, 358 F.3d 344, 350 (5th Cir. 2004) (en banc).

Revocation of supervised release is mandatory under certain circumstances. 18 U.S.C. § 3583(g). Among other things, rev *986 ocation is required where a defendant “possesses a controlled substance,” “refuses to comply with drug testing imposed as a condition of supervised release,” or “as a part of drug testing, tests positive for illegal controlled substances more than 3 times over the course of 1 year.” 18 U.S.C. § 3583(g). That said, 18 U.S.C. § 3583(d) provides that where a defendant fails a drug test, “[t]he court shall consider whether the availability of appropriate substance abuse treatment programs, or an individual’s current or past participation in such programs, warrants an exception ... from the rule of section 3583(g).”

Both of Brooker’s arguments on appeal rely on an underlying proposition that he fits within § 3583(d)’s treatment exception. Because Brooker’s term of supervised release was revoked both due to drug possession and his refusal to comply with drug testing—not just because he failed a drug test—it is unclear whether Brooker qualifies for the treatment exception under our existing case law. While this Court has not annunciated a rule in a published opinion, we have several times declined to apply the treatment exception where the established violations of a defendant’s conditions of supervised release included more than failing a drug test. See United States v. Turlich, 440 Fed.Appx. 282, 282-83 (5th Cir. 2011) (per curiam); United States v. Kindley, 271 Fed.Appx. 429 (5th Cir. 2008) (per curiam); United States v. Harper, 34 Fed.Appx. 150 (5th Cir. 2002) (per curiam).

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. John Brooker, 858 F.3d 983, 2017 WL 2466733, 2017 U.S. App. LEXIS 10152 (5th Cir. 2017).

858 F.3d 983 (United States v. John Brooker) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Moses
Fifth Circuit, 2026
United States v. Morgan
Fifth Circuit, 2026
United States v. Goodwill
Fifth Circuit, 2026
United States v. Dehoyos
Fifth Circuit, 2026
United States v. Johnson
Fifth Circuit, 2022
United States v. John Stern
Fifth Circuit, 2019
United States v. Brendon Hole
Eighth Circuit, 2019
United States v. Jack Garner
Sixth Circuit, 2019
United States v. Rocky Wallace
697 F. App'x 375 (Fifth Circuit, 2017)